Stocks / NASDAQ / BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc.

Our Opinion

BioDelivery Sciences International, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.


BioDelivery Sciences Announces Initial Results of Phase 1 Clinical Study of Bioral Amphotericin B

The preliminary pharmacokinetic evaluation also revealed that plasma concentrations were comparable to those seen in prior animal toxicology studies using the same formulation. In previous animal studies conducted by BDSI, doses used in toxicology studies have been shown to produce measureable tissue concentrations and efficacy against the fungal infections candidiasis and aspergillosis.

Company Description

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. [Source: MarketWatch]